DiabetesNCT00339781
Predictive and Protective Factors in the Cause of Diabetes - A Study in Twins
An observational study of Diabetes and Type 1 Diabetes, run by National Institute of Environmental Health Sciences (NIEHS) at 1 site in United Kingdom.
Trial summary
This study, conducted at St. Bartholomew's Hospital, London, England, will determine whether cells passed from mother to offspring during pregnancy increase or decrease the child's risk of developing type 1 diabetes. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Diabetes, Type 1 Diabetes
- How many people
- 240 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Feb 2005to Sep 2007
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- The twin subjects who are the focus of this study will be greater than or equal to 12 years of age and diabetes discordance must have been present for greater than 5 years.
- The subjects must be able to understand and sign the informed consent documents, and thus severe mental incapacity is an exclusion criterion.
- Female twins must not be currently pregnant or have had a miscarriage or abortion. Identical twin pairs (female or male) must not have undergone an organ or bone marrow transplantation, or a blood transfusion at any time in their lives.
- There are no other health status criteria for participating in this study, except as noted above.
- Patients may have other preexisting conditions.
- There are no age limits for the offspring of the twins.
- Subjects will not be excluded based on gender, ethnicity, race or religion.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predictive and Protective Factors in the Cause of Diabetes: A Study in Twins
This study, conducted at St. Bartholomew's Hospital, London, England, will determine whether cells passed from mother to offspring during pregnancy increase or decrease the child's risk of developing type 1 diabetes. Previous research has shown that certain cells that can be passed from mothers to their children during pregnancy may affect the child's chance of developing other autoimmune diseases. The cells from the mother may persist in the child's blood for years after birth and stimulate the child's immune system in such a way that may either increase or decrease the chance of the child developing diabetes. This study will determine whether these cells are present in identical twins, where only one of the twins has type 1 diabetes.
Participants in the British Diabetic Twins Study in England may be eligible to participate. Of each twin pair in the study, one must have type 1 diabetes and the other must be free of the disease. The twins' mother must be alive and willing to provide a blood sample. For female twins only, their children must be alive and willing to provide either a blood or a buccal cell sample (cheek swab).
Read more
Participants undergo the following procedures:
- Both twins in each twin pair provide a blood sample collected on a single occasion.
- The mother of each twin pair provides a blood sample collected on a single occasion.
- Children of female twins provide a single sample from either the mouth or blood. For children younger than 12 years of age, a cell sample is collected from the inside of the mouth (buccal) using a toothbrush. The child strokes the inside (cheek) of the mouth with the toothbrush ten times on each side, spits this into a collection vial, immediately rinses the mouth with water and adds this rinse to the sample collection vial. Children over 12 years of age may provide either a buccal cell sample or a blood sample.
Read the detailed description
Type 1 diabetes is one of several autoimmune diseases of unclear etiology in which the discordance rate between identical twins is between 30-40%, even after many years of follow-up. This intermediate discordance rate indicates that there are clearly genetic factors at play in susceptibility to type 1 diabetes, with most genetic contribution coming from the HLA locus. However, this discordance rate also means that other, non-genetic factors, possibly environmental, lead to the development of disease in only one of two genetically identical individuals. No consensus exists on the nature of these putative environmental differences, which are all the more remarkable for occurring in twins that generally share the same intrauterine, family and school environment.
Recent evidence has suggested that the development of certain autoimmune diseases, particularly scleroderma, may be influenced by microchimerism: Both fetomaternal microchimerisms (persistence of fetal cells in the maternal circulation after birth of the child) and maternofetal microchimerism (persistence of maternal cells in the child's circulation for years after birth) have been suggested as creating an abnormal environment that might stimulate the development of autoimmunity in genetically susceptible individuals. The reverse is also possible, i.e., that these abnormal cells may stimulate the immune system in such a way that autoimmunity does not develop.
Identical or monozygotic (MZ) twins who are discordant for type 1 diabetes offer a unique experimental model in which to test the hypothesis that quantitative differences in persistent maternofetal microchimerism influence the development of type 1 diabetes in these genetically susceptible individuals. This study will use pairs of MZ twins discordant for the type 1 diabetes that are already participating in the British Diabetic Twins Study being conducted by Dr. David Leslie at St. Bartholomew's Hospital in London, UK. If the mothers of the twins (both female and male) and offspring of the female twins (only) are available for study, they will be asked to provide a single blood sample (twins, mothers, offspring greater than 12 years of age) or buccal cell sample (offspring less than or equal to 12 years of age) from which DNA will be purified. This is to confirm the origin of the chimeric cells; since cells are passed from the mothers to the offspring during pregnancy, we require (DNA) samples from the mothers of all twins (male and female) who participate in this study. But since the opposite is true, that cells can also be passed from offspring to their mothers during pregnancy, we will require (DNA) samples from the female twins' offspring to determine the true origin of any chimeric cells. The DNA will be used for HLA genotyping to identify nonshared HLA alleles that can be used to develop specific assays for the persistence of maternal DNA in the twins' circulation and quantitative PCR of the mother's genotype in CD3+ cells isolated from the twins. Since trafficking of chimeric cells can be bi-directional, twins who have had offspring of their own may have chimeric cells of both fetal and maternal origin in their circulation. To confirm the origin of the chimeric cells, the blood or buccal cells collected from the offspring of the twins will be genotyped and these compared to the genotypes of the twins' mothers. Blood will be drawn and DNA purified by Dr. Leslie's group in London; the genotyping and quantitative PCR will be performed by Dr. Artlett's group at Thomas Jefferson University, Philadelphia, which has been studying microchimerism since 1998. Results of the study may provide evidence in support of microchimerism as an influential factor in the development of type 1 diabetes. Evidence in support to this concept would be an important addition to the literature on "environmental" factors that influence type 1 diabetes etiology, and also suggest potential immunosuppression or other strategies in type 1 diabetes prevention.
- Conditions
- Diabetes, Type 1 Diabetes
- Keywords
- Fetomaternal Microchimerism, Cell Trafficking, Discordant Twins, Maternofetal Microchimerism, Diabetes Type I, Twins
- Medical subject headings
- Diabetes Mellitus, Diabetes Mellitus, Type 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jun 2006 (estimated)
- Study startFeb 2005
- Primary completionSep 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Enrolment
- 240 participants
Sponsor and investigators
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- Sponsor type
- US National Institutes of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00339781
- Sponsor's protocol ID
- 999905109
- Other IDs
- 05-E-N109
- Status last verified
- Sep 2009
- First submitted
- 19 Jun 2006
- Last updated
- 23 Sep 2009
- Results posted
- No
Publications
Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell. 1996 May 3;85(3):291-7. doi: 10.1016/s0092-8674(00)81106-x. No abstract available.
PubMed 8616883Christau B, Kromann H, Christy M, Andersen OO, Nerup J. Incidence of insulin-dependent diabetes mellitus (0--29 years at onset) in Denmark. Acta Med Scand Suppl. 1979;624:54-60. doi: 10.1111/j.0954-6820.1979.tb00719.x.
PubMed 284714Gottlieb MS, Root HF. Diabetes mellitus in twins. Diabetes. 1968 Nov;17(11):693-704. doi: 10.2337/diab.17.11.693. No abstract available.
PubMed 5687346
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive and Protective Factors in the Cause of Diabetes: A Study in Twins
- ClinicalTrials.gov ID
- NCT00339781
- Acronym / sponsor ID
- 999905109
- Conditions
- Diabetes, Type 1 Diabetes
- Keywords
- Fetomaternal Microchimerism, Cell Trafficking, Discordant Twins, Maternofetal Microchimerism, Diabetes Type I, Twins
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 240 participants
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)US National Institutes of Health
- Study start
- Feb 2005
- Primary completion
- Sep 2007 (actual)
- First posted
- 21 Jun 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study, conducted at St. Bartholomew's Hospital, London, England, will determine whether cells passed from mother to offspring during pregnancy increase or decrease the child's risk of developing type 1 diabetes. Previous research has shown that certain cells that can be passed from mothers to their children during pregnancy may affect the child's chance of developing other autoimmune diseases. The cells from the mother may persist in the child's blood for years after birth and stimulate the child's immune system in such a way that may either increase or decrease the chance of the child developing diabetes. This study will determine whether these cells are present in identical twins, where only one of the twins has type 1 diabetes.
Participants in the British Diabetic Twins Study in England may be eligible to participate. Of each twin pair in the study, one must have type 1 diabetes and the other must be free of the disease. The twins' mother must be alive and willing to provide a blood sample. For female twins only, their children must be alive and willing to provide either a blood or a buccal cell sample (cheek swab).
Participants undergo the following procedures:
- Both twins in each twin pair provide a blood sample collected on a single occasion.
- The mother of each twin pair provides a blood sample collected on a single occasion.
- Children of female twins provide a single sample from either the mouth or blood. For children younger than 12 years of age, a cell sample is collected from the inside of the mouth (buccal) using a toothbrush. The child strokes the inside (cheek) of the mouth with the toothbrush ten times on each side, spits this into a collection vial, immediately rinses the mouth with water and adds this rinse to the sample collection vial. Children over 12 years of age may provide either a buccal cell sample or a blood sample.
Detailed description
Type 1 diabetes is one of several autoimmune diseases of unclear etiology in which the discordance rate between identical twins is between 30-40%, even after many years of follow-up. This intermediate discordance rate indicates that there are clearly genetic factors at play in susceptibility to type 1 diabetes, with most genetic contribution coming from the HLA locus. However, this discordance rate also means that other, non-genetic factors, possibly environmental, lead to the development of disease in only one of two genetically identical individuals. No consensus exists on the nature of these putative environmental differences, which are all the more remarkable for occurring in twins that generally share the same intrauterine, family and school environment.
Recent evidence has suggested that the development of certain autoimmune diseases, particularly scleroderma, may be influenced by microchimerism: Both fetomaternal microchimerisms (persistence of fetal cells in the maternal circulation after birth of the child) and maternofetal microchimerism (persistence of maternal cells in the child's circulation for years after birth) have been suggested as creating an abnormal environment that might stimulate the development of autoimmunity in genetically susceptible individuals. The reverse is also possible, i.e., that these abnormal cells may stimulate the immune system in such a way that autoimmunity does not develop.
Identical or monozygotic (MZ) twins who are discordant for type 1 diabetes offer a unique experimental model in which to test the hypothesis that quantitative differences in persistent maternofetal microchimerism influence the development of type 1 diabetes in these genetically susceptible individuals. This study will use pairs of MZ twins discordant for the type 1 diabetes that are already participating in the British Diabetic Twins Study being conducted by Dr. David Leslie at St. Bartholomew's Hospital in London, UK. If the mothers of the twins (both female and male) and offspring of the female twins (only) are available for study, they will be asked to provide a single blood sample (twins, mothers, offspring greater than 12 years of age) or buccal cell sample (offspring less than or equal to 12 years of age) from which DNA will be purified. This is to confirm the origin of the chimeric cells; since cells are passed from the mothers to the offspring during pregnancy, we require (DNA) samples from the mothers of all twins (male and female) who participate in this study. But since the opposite is true, that cells can also be passed from offspring to their mothers during pregnancy, we will require (DNA) samples from the female twins' offspring to determine the true origin of any chimeric cells. The DNA will be used for HLA genotyping to identify nonshared HLA alleles that can be used to develop specific assays for the persistence of maternal DNA in the twins' circulation and quantitative PCR of the mother's genotype in CD3+ cells isolated from the twins. Since trafficking of chimeric cells can be bi-directional, twins who have had offspring of their own may have chimeric cells of both fetal and maternal origin in their circulation. To confirm the origin of the chimeric cells, the blood or buccal cells collected from the offspring of the twins will be genotyped and these compared to the genotypes of the twins' mothers. Blood will be drawn and DNA purified by Dr. Leslie's group in London; the genotyping and quantitative PCR will be performed by Dr. Artlett's group at Thomas Jefferson University, Philadelphia, which has been studying microchimerism since 1998. Results of the study may provide evidence in support of microchimerism as an influential factor in the development of type 1 diabetes. Evidence in support to this concept would be an important addition to the literature on "environmental" factors that influence type 1 diabetes etiology, and also suggest potential immunosuppression or other strategies in type 1 diabetes prevention.
Study design
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- The twin subjects who are the focus of this study will be greater than or equal to 12 years of age and diabetes discordance must have been present for greater than 5 years.
- The subjects must be able to understand and sign the informed consent documents, and thus severe mental incapacity is an exclusion criterion.
- Female twins must not be currently pregnant or have had a miscarriage or abortion. Identical twin pairs (female or male) must not have undergone an organ or bone marrow transplantation, or a blood transfusion at any time in their lives.
- There are no other health status criteria for participating in this study, except as noted above.
- Patients may have other preexisting conditions.
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2009.
- Background: PubMed 8616883Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell. 1996 May 3;85(3):291-7. doi: 10.1016/s0092-8674(00)81106-x. No abstract available.
- Background: PubMed 284714Christau B, Kromann H, Christy M, Andersen OO, Nerup J. Incidence of insulin-dependent diabetes mellitus (0--29 years at onset) in Denmark. Acta Med Scand Suppl. 1979;624:54-60. doi: 10.1111/j.0954-6820.1979.tb00719.x.
- Background: PubMed 5687346Gottlieb MS, Root HF. Diabetes mellitus in twins. Diabetes. 1968 Nov;17(11):693-704. doi: 10.2337/diab.17.11.693. No abstract available.
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes and Type 1 Diabetes, run by National Institute of Environmental Health Sciences (NIEHS) at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00339781, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2009.